Stocks股票 / Health Care / COR
COR US listed · USD美股 · 美元
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023.Cencora公司,前身为AmerisourceBergen,是一家美国药品批发和分销公司及合同研究机构,由Bergen Brunswig和AmeriSource于2001年合并而成,2023年更名为Cencora。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-08-14Earnings财务业绩
Estimates roughly stable预期基本稳定
Beat in 3 of last 4 quarters近 4 季中 3 季超预期
Post-earnings drift: +2.8% (20d)财报后漂移:+2.8%(20日)
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 1.6%
Valuation估值
Roughly fair vs sector相对行业估值合理| Multiple指标 | COR | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(历史) | 38.80x | 30.88 | |
| P/B市净率 | 31.60x | 3.54 | |
| P/S市销率 | 0.19x | 3.20 | |
| Earnings yield盈利收益率 | 2.58% | 2.51 | |
| FCF yield自由现金流收益率 | 5.32% | 4.00 | |
| Shareholder yield股东收益率 | 1.45% | 1.83 | |
| EV/EBITDA企业价值/EBITDA | 17.29x | 19.05 | |
| P/FCF市值/自由现金流 | 18.80x | 22.49 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Options positioning期权持仓
as of last close截至上一收盘Market makers are net long gamma — price pinned near current level做市商净持有正伽玛,价格倾向于在当前水平附近震荡
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$1.3M net (2 buyers, 1 sellers)-$1.3M 净值(2 买家,1 卖家)
Signal history信号历史
engine events引擎事件Company profile公司档案
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023.Cencora公司,前身为AmerisourceBergen,是一家美国药品批发和分销公司及合同研究机构,由Bergen Brunswig和AmeriSource于2001年合并而成,2023年更名为Cencora。
- Capital intensity rising
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(静态) | 38.8× | 30.9× | 35% |
| Price / Book市净率 | 31.6× | 3.5× | 3% |
| Price / Sales市销率 | 0.2× | 3.2× | 99% |
| EV / EBITDAEV/EBITDA | 17.3× | 19.1× | 57% |
| Earnings yield盈利收益率 | 2.6% | 2.5% | 52% |
| Free-cash-flow yield自由现金流收益率 | 6.4% | 5.3% | 69% |
| Shareholder yield股东综合回报率 | 1.4% | 1.8% | 39% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -4.6% | +1.2% |
| 1 Month近1月 | +2.6% | +3.5% |
| 3 Months近3月 | +20.3% | +5.2% |
| 6 Months近6月 | -13.9% | +14.4% |
| Year to date年初至今 | -8.1% | +14.2% |
| 1 Year近1年 | +7.3% | +21.6% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $189.9B | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| EPS每股收益 | $-16.65 | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Free cash flow自由现金流 | $1.8B | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Gross margin毛利率 | 2.7% | 3.2% | 3.5% | 3.4% | 3.4% | 3.6% |
| Net margin净利率 | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
| FCF margin自由现金流利润率 | 1.0% | 1.0% | 0.9% | 1.3% | 1.0% | 1.0% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: accruals trending up over 6 fiscal years — earnings increasingly not cash-backed盈利质量:应计利润在 6 个财年间走高——盈利的现金支撑减弱
- Working capital: working capital roughly in line with sales营运资本:营运资本与销售大致同步
- Pricing power: soft gross profitability vs peers定价能力:毛利能力弱于同业
- Capital discipline: investment near the peer median资本纪律:投资力度接近同业中位
- Balance sheet: Altman Z 4.82 — safe zone资产负债表:Altman Z 4.82——安全区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Mar 2026 | $4.75 | $4.80 | -1.0% |
| Dec 2025 | $4.08 | $4.07 | +0.2% |
| Sep 2025 | $3.84 | $3.79 | +1.3% |
| Jun 2025 | $4.00 | $3.78 | +5.8% |